KalVista Pharmaceuticals (KALV) Total Current Liabilities (2016 - 2024)
Historic Total Current Liabilities for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q4 2024 value amounting to $26.1 million.
- KalVista Pharmaceuticals' Total Current Liabilities changed N/A to $26.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $26.1 million, marking a year-over-year change of. This contributed to the annual value of $22.8 million for FY2024, which is N/A changed from last year.
- KalVista Pharmaceuticals' Total Current Liabilities amounted to $26.1 million in Q4 2024.
- KalVista Pharmaceuticals' Total Current Liabilities' 5-year high stood at $26.1 million during Q4 2024, with a 5-year trough of $6.5 million in Q1 2021.
- For the 4-year period, KalVista Pharmaceuticals' Total Current Liabilities averaged around $15.5 million, with its median value being $15.9 million (2023).
- In the last 5 years, KalVista Pharmaceuticals' Total Current Liabilities tumbled by 5723.47% in 2020 and then soared by 5858.34% in 2024.
- Quarter analysis of 4 years shows KalVista Pharmaceuticals' Total Current Liabilities stood at $9.5 million in 2020, then plummeted by 31.65% to $6.5 million in 2021, then soared by 172.34% to $17.8 million in 2023, then soared by 47.11% to $26.1 million in 2024.
- Its last three reported values are $26.1 million in Q4 2024, $22.2 million for Q4 2024, and $22.4 million during Q3 2024.